health Aficamten Superior to Metoprolol for Hypertrophic Cardiomyopathy Exercise Performance
New Phase III trial data shows the cardiac myosin inhibitor Aficamten significantly improves exercise capacity over the standard therapy, Metoprolol, in patients with obstructive hypertrophic cardiomyopathy.
